Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
Childhood cancer is considered rare, corresponding to ~3% of all malignant neoplasms in the human population. The World Health Organization (WHO) reports a universal occurrence of more than 15 cases per 100,000 inhabitants around the globe, and despite improvements in diagnosis, treatment and suppor...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/2/664 |
| _version_ | 1797618703535177728 |
|---|---|
| author | Marina Ferreira Candido Mariana Medeiros Luciana Chain Veronez David Bastos Karla Laissa Oliveira Julia Alejandra Pezuk Elvis Terci Valera María Sol Brassesco |
| author_facet | Marina Ferreira Candido Mariana Medeiros Luciana Chain Veronez David Bastos Karla Laissa Oliveira Julia Alejandra Pezuk Elvis Terci Valera María Sol Brassesco |
| author_sort | Marina Ferreira Candido |
| collection | DOAJ |
| description | Childhood cancer is considered rare, corresponding to ~3% of all malignant neoplasms in the human population. The World Health Organization (WHO) reports a universal occurrence of more than 15 cases per 100,000 inhabitants around the globe, and despite improvements in diagnosis, treatment and supportive care, one child dies of cancer every 3 min. Consequently, more efficient, selective and affordable therapeutics are still needed in order to improve outcomes and avoid long-term sequelae. Alterations in kinases’ functionality is a trademark of cancer and the concept of exploiting them as drug targets has burgeoned in academia and in the pharmaceutical industry of the 21st century. Consequently, an increasing plethora of inhibitors has emerged. In the present study, the expression patterns of a selected group of kinases (including tyrosine receptors, members of the PI3K/AKT/mTOR and MAPK pathways, coordinators of cell cycle progression, and chromosome segregation) and their correlation with clinical outcomes in pediatric solid tumors were accessed through the R2: Genomics Analysis and Visualization Platform and by a thorough search of published literature. To further illustrate the importance of kinase dysregulation in the pathophysiology of pediatric cancer, we analyzed the vulnerability of different cancer cell lines against their inhibition through the Cancer Dependency Map portal, and performed a search for kinase-targeted compounds with approval and clinical applicability through the CanSAR knowledgebase. Finally, we provide a detailed literature review of a considerable set of small molecules that mitigate kinase activity under experimental testing and clinical trials for the treatment of pediatric tumors, while discuss critical challenges that must be overcome before translation into clinical options, including the absence of compounds designed specifically for childhood tumors which often show differential mutational burdens, intrinsic and acquired resistance, lack of selectivity and adverse effects on a growing organism. |
| first_indexed | 2024-03-11T08:16:08Z |
| format | Article |
| id | doaj.art-b9a541c16da1407b8ddb186acba17452 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T08:16:08Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-b9a541c16da1407b8ddb186acba174522023-11-16T22:43:00ZengMDPI AGPharmaceutics1999-49232023-02-0115266410.3390/pharmaceutics15020664Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current ScenarioMarina Ferreira Candido0Mariana Medeiros1Luciana Chain Veronez2David Bastos3Karla Laissa Oliveira4Julia Alejandra Pezuk5Elvis Terci Valera6María Sol Brassesco7Department of Cell Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilRegional Blood Center, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-901, SP, BrazilDepartment of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-901, SP, BrazilDepartament of Biotechnology and Innovation, Anhanguera University of São Paulo, UNIAN/SP, São Paulo 04119-001, SP, BrazilDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartament of Biotechnology and Innovation, Anhanguera University of São Paulo, UNIAN/SP, São Paulo 04119-001, SP, BrazilChildhood cancer is considered rare, corresponding to ~3% of all malignant neoplasms in the human population. The World Health Organization (WHO) reports a universal occurrence of more than 15 cases per 100,000 inhabitants around the globe, and despite improvements in diagnosis, treatment and supportive care, one child dies of cancer every 3 min. Consequently, more efficient, selective and affordable therapeutics are still needed in order to improve outcomes and avoid long-term sequelae. Alterations in kinases’ functionality is a trademark of cancer and the concept of exploiting them as drug targets has burgeoned in academia and in the pharmaceutical industry of the 21st century. Consequently, an increasing plethora of inhibitors has emerged. In the present study, the expression patterns of a selected group of kinases (including tyrosine receptors, members of the PI3K/AKT/mTOR and MAPK pathways, coordinators of cell cycle progression, and chromosome segregation) and their correlation with clinical outcomes in pediatric solid tumors were accessed through the R2: Genomics Analysis and Visualization Platform and by a thorough search of published literature. To further illustrate the importance of kinase dysregulation in the pathophysiology of pediatric cancer, we analyzed the vulnerability of different cancer cell lines against their inhibition through the Cancer Dependency Map portal, and performed a search for kinase-targeted compounds with approval and clinical applicability through the CanSAR knowledgebase. Finally, we provide a detailed literature review of a considerable set of small molecules that mitigate kinase activity under experimental testing and clinical trials for the treatment of pediatric tumors, while discuss critical challenges that must be overcome before translation into clinical options, including the absence of compounds designed specifically for childhood tumors which often show differential mutational burdens, intrinsic and acquired resistance, lack of selectivity and adverse effects on a growing organism.https://www.mdpi.com/1999-4923/15/2/664childhood cancerkinaseschemical inhibitorsclinical trials |
| spellingShingle | Marina Ferreira Candido Mariana Medeiros Luciana Chain Veronez David Bastos Karla Laissa Oliveira Julia Alejandra Pezuk Elvis Terci Valera María Sol Brassesco Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario Pharmaceutics childhood cancer kinases chemical inhibitors clinical trials |
| title | Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario |
| title_full | Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario |
| title_fullStr | Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario |
| title_full_unstemmed | Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario |
| title_short | Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario |
| title_sort | drugging hijacked kinase pathways in pediatric oncology opportunities and current scenario |
| topic | childhood cancer kinases chemical inhibitors clinical trials |
| url | https://www.mdpi.com/1999-4923/15/2/664 |
| work_keys_str_mv | AT marinaferreiracandido drugginghijackedkinasepathwaysinpediatriconcologyopportunitiesandcurrentscenario AT marianamedeiros drugginghijackedkinasepathwaysinpediatriconcologyopportunitiesandcurrentscenario AT lucianachainveronez drugginghijackedkinasepathwaysinpediatriconcologyopportunitiesandcurrentscenario AT davidbastos drugginghijackedkinasepathwaysinpediatriconcologyopportunitiesandcurrentscenario AT karlalaissaoliveira drugginghijackedkinasepathwaysinpediatriconcologyopportunitiesandcurrentscenario AT juliaalejandrapezuk drugginghijackedkinasepathwaysinpediatriconcologyopportunitiesandcurrentscenario AT elvistercivalera drugginghijackedkinasepathwaysinpediatriconcologyopportunitiesandcurrentscenario AT mariasolbrassesco drugginghijackedkinasepathwaysinpediatriconcologyopportunitiesandcurrentscenario |